

M.D. (Sem. Final) Examination June - 2023

Pharmacology (Paper I)

General Pharmacology and Applied Sciences

: 3 H	ours]	[Total Marks: 100
: / In	structions	
Fill u	ર્શાવેલ ☞ નિશાનીવાળી વિગતો ઉત્તરવહી પર અવશ્ય લખવી. p strictly the details of ☞ signs on your answer book	Seat No.:
_	e of the Examination:	
	M.D. (Sem. Final)	
Name	e of the Subject :	
-	Pharmacology (Paper I) General Pharmacology and Applied sciences	Student's Signature
Subje	ct Code No.: 2106121201010001	
Figu	questions are compulsory. ures to the right indicate maximum marks. strate your answers with examples and figures/diagra	ams if needed
Figi	ures to the right indicate maximum marks. strate your answers with examples and figures/diagra Discuss in detail modulators of β adrenergic recept	tors. 4
Fig	Lires to the right indicate maximum marks. Strate your answers with examples and figures/diagra Discuss in detail modulators of β adrenergic recept Describe in brief:	
Figi	Describe in brief: G- Protein coupled receptors	tors. 4
Figu Illu	Lires to the right indicate maximum marks. Strate your answers with examples and figures/diagra Discuss in detail modulators of β adrenergic recept Describe in brief:	tors. 4
Figu Illu a)	Describe in brief: G- Protein coupled receptors	fors. 4 [15 x 2] = 3
Figu Illu a)	Discuss in detail modulators of β adrenergic recept Describe in brief: G- Protein coupled receptors Pharmacovigilance in India	tors. 4
Figu Illu a) b)	Discuss in detail modulators of β adrenergic recept Describe in brief: G- Protein coupled receptors Pharmacovigilance in India Write short notes on:	fors. 4 [15 x 2] = 3



M. D. (Sem. Final) Examination June - 2023

Pharmacology (Paper II)

Systemic Pharmacology, Chemotherapy & Therapeutics

(9)	નીચે	દર્શાવેલ 🖝 નિશાનીવાળી વિગતો ઉત્તરવહી પર અવશ્ય લખવી.	Seat No.:
		up strictly the details of signs on your answer book	
	_	ne of the Examination: M. D. (Sem. Final)	
	۰ -	ne of the Subject :	
		Pharmacology (Paper II) Systemic Pharmacology, Chemotherapy & Therapeutics	
	Subje	ect Code No.: 2106121201020001	Student's Signature
(2)	All	questions are compulsory.	
(3)	Figu		Sold and the Control of the Control
(3) (4)		ares to the right indicate maximum marks.	ums if needed.
			nms if needed.
		ares to the right indicate maximum marks.	
(4) 1.		ares to the right indicate maximum marks. strate your answers with examples and figures/diagra Classify fluoroquinolones. Describe their mechanis	sm of action, clinical
(4)		cares to the right indicate maximum marks. Strate your answers with examples and figures/diagra Classify fluoroquinolones. Describe their mechanis uses & ADRs in detail. Describe in brief:	sm of action, clinical
(4) 1.	Illus	classify fluoroquinolones. Describe their mechanisuses & ADRs in detail.	sm of action, clinical 40 $[15 \times 2] = 30$
(4) 1. 2.	Illus a)	Classify fluoroquinolones. Describe their mechanisuses & ADRs in detail. Describe in brief: Antiretroviral therapy Digoxin: mechanism of action, ADRs & therapeuti	sm of action, clinical 40 $[15 \times 2] = 30$ c status
(4) 1.	a) b)	Classify fluoroquinolones. Describe their mechanisuses & ADRs in detail. Describe in brief: Antiretroviral therapy Digoxin: mechanism of action, ADRs & therapeuti	sm of action, clinical 40 $[15 \times 2] = 30$
(4) 1. 2.	a) b)	Classify fluoroquinolones. Describe their mechanisuses & ADRs in detail. Describe in brief: Antiretroviral therapy Digoxin: mechanism of action, ADRs & therapeuti Write short notes on: 'AWaRe' guideline	sm of action, clinical 40 $[15 \times 2] = 30$ c status
(4) 1. 2.	a) b)	Classify fluoroquinolones. Describe their mechanisuses & ADRs in detail. Describe in brief: Antiretroviral therapy Digoxin: mechanism of action, ADRs & therapeuti	sm of action, clinical 40 $[15 \times 2] = 30$ c status



M. D. (Sem. Final) Examination June - 2023

Pharmacology (Paper III)

Experimental Pharmacology, Bioassay, Biostatistics

& Systemic Pharmacology

) (नि	ીચે દર્શાવેલ ☞ નિશાનીવાળી વિગતો ઉત્તરવહી પર અવશ્ય લખવી. ill up strictly the details of ☞ signs on your answer book	Seat No.:
N	ame of the Examination:	
-	M. D. (Sem. Final)	
N	ame of the Subject :	
	Pharmacology (Paper III) Experimental Pharmacology, Bioassay, Biostatistics & Systemic Pharmacology	State of Sta
s	subject Code No.: 2106121201030001	Student's Signature
) A	all questions are compulsory.	
	ill duestions are comparisory.	
) F	igures to the right indicate maximum marks.	
) F	igures to the right indicate maximum marks. llustrate your answers with examples and figures/diagra	ams if needed.
) F	igures to the right indicate maximum marks.	
) F	igures to the right indicate maximum marks. llustrate your answers with examples and figures/diagra	
) F) II	igures to the right indicate maximum marks. llustrate your answers with examples and figures/diagra Describe experimental models for anti-inflammato	ory agents screening. 40
) F) II	igures to the right indicate maximum marks. llustrate your answers with examples and figures/diagra Describe experimental models for anti-inflammato Describe in brief:	ory agents screening. 40
) F) II	igures to the right indicate maximum marks. llustrate your answers with examples and figures/diagra Describe experimental models for anti-inflammato Describe in brief: a) Glucocorticoids: Uses & misuses	ory agents screening. 40
) F) II	igures to the right indicate maximum marks. Illustrate your answers with examples and figures/diagra Describe experimental models for anti-inflammato Describe in brief: a) Glucocorticoids: Uses & misuses b) Fibrinolytics in therapeutics	ory agents screening. 40 $[15 \times 2] = 30$
) F) II	igures to the right indicate maximum marks. llustrate your answers with examples and figures/diagra Describe experimental models for anti-inflammato Describe in brief: a) Glucocorticoids: Uses & misuses b) Fibrinolytics in therapeutics Write short notes on:	ory agents screening. 40 $[15 \times 2] = 30$



M.D. (Sem. Final) Examination June - 2023

Clinical Pharmacology and Recent Advances (Paper IV)

Time	: 3 H	ours]	[Total Marks: 100	
સૂચન	: / In	structions		
(9)	Fill up	ર્શાવેલ ☞ નિશાનીવાળી વિગતો ઉત્તરવહી પર અવશ્ય લખવી. p strictly the details of ☞ signs on your answer book e of the Examination:	Seat No.:	
1	_	M.D. (Sem. Final)		
	_	e of the Subject :		
. 5		Clinical Pharmacology and Recent Advances (Paper IV)		
	Subjec	ct Code No.: 2106121201040001	Student's Signature	
(2)	A11 a	questions are compulsory.		
(2)		res to the right indicate maximum marks.		
(4)	Illustrate your answers with examples and figures / diagrams if needed.			
(.)		ka dagara karangan karangan karangan bangan ban		
1.		Newer development in treatment of diabetes melling	us. 40	
2.		Describe in brief:	$[15 \times 2] = 30$	
	a)	Novel drugs in the treatment of bronchial asthma		
	b)	Pharmacogenetics		
3.		Write short notes on:	$[10 \times 3] = 30$	
	a)	Competency based medical education		
	b)	Botulinum toxin: Boon or bane?		
	c)	Emerging trends in vaccination		

CS So